|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Docetaxel,cisplatin,and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer显示文摘 | Hurley J Doliny P Reis I | | 0，，12： | 1 |
| 2 | Neoadjuvant Hereeptin/taxotere/ cisplatin in the treatment of locally advanced and in flammatory breast cancer显示文摘 | Hurley J Doliny P Silva O | 2002 | Proc Am Soc Clin Oncol2002，21，1： | 1 |
| 3 | Docetaxel, cisplatin, and trastu- zumab as primary systemic therapy for human epidermal growth factor receptor2-positive locally advanced breast cancer显示文摘 | Hurley J Doliny P Reis I | 2006 | Clin Onco12006，24，18： | 1 |
| 4 | Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers 显示文摘 | Lee Y J Doliny P Gomez-Fcrnandez C | 2004 | Clin Breast Cancer2004，5，5： | 1 |
| 5 | Docetaxel cisplatin and trastu- zumab as primary systemic therapy for human epidermal growth factor 2-positive locally advanced breast cancer 显示文摘 | Hurley J Doliny P Reis I | 2006 | J Clin 0n- col2006，24，12： | 1 |
| 6 | High complete pathologic response rate of locally advanced breast cancers (LABC) to neoadjuvant docetaxel and cisplatin chemotherapy显示文摘 | Hurley J Doliny P Gomez C | 2000 | Pro Am Soc Clin Oncol2000，19，： | 1 |
| 7 | High complete pathologic response rate of locally advanced breast cancers (LABC) to neo - adjuvant docetaxel and cisplatin chemotherapy 显示文摘 | Hurley J Doliny P Gomez C | 2000 | Pro Am Soc Clin Oncol2000，19，： | 1 |
| 8 | Hight complete pathologic response rates of locally advanced breast cancers (LABC) to neoadjurant Docetaxel and Cisplatin chemotherapy显示文摘 | Doliny P Gomez C | 2000 | Proceeding of ASCO2000，19，： | 1 |
| 9 | Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers显示文摘 | Lee Y J Doliny P Gomez-Fernandez C | 2004 | Clin Breast Cancer2004，5，5： | 1 |
| 10 | High complete pathologic re--sponse rate of locally advanced breast cancers (LABC) to neo--adjuvant docetaxel and cisplatin chemotherapy显示文摘 | Hurley J Doliny P Gomez C | 2000 | Pro Am SocClin Oncol2000，19，： | 1 |
| 11 | Docetaxel,cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast caficer 显示文摘 | Hurley J Doliny P Reis I | 2006 | J Clin Oncol2006，24，12： | 1 |
| 12 | Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer 显示文摘 | Hurley J Doliny P Reis I | 2006 | J Clin Oncol2006，24，12： | 1 |
| 13 | Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-pasitive locally advanced breast cancer 显示文摘 | Hurley J Doliny P Reis I | 2006 | J Clin Oncol2006，24，： | 1 |
| 14 | Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epi- dermal growth factor receptor 2-positive locally advanced breast cancer显示文摘 | Hurley J Doliny P Reis I | 2006 | J Clin Oncol2006，24，12： | 1 |
| 15 | MRI of car occupants with whiplash injury显示文摘 | VOYVODIC P DOLINIS J MOORE VM | 1997 | Neuroradiology1997，39，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员